Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J RIIS

Showing results (61-70 of 128) with videos related to

Pageof 13
Sort By:
BMC Clinical Pharmacology|September 11, 2008
Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of Salmon CalcitoninMorten A Karsdal, Inger Byrjalsen, Bente J Riis, et al.
BMC Clinical Pharmacology|December 6, 2008
Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteoporosis with oral calcitoninM A Karsdal, I Byrjalsen, B J Riis, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|February 1, 1991
Potential risk factors for development of postmenopausal osteoporosis--examined over a 12-year periodM A Hansen, K Overgaard, B J Riis, et al.
BMJ (Clinical Research Ed.)|August 19, 1989
Effect of salcatonin given intranasally on early postmenopausal bone lossK Overgaard, B J Riis, C Christiansen, et al.
Annals of the Rheumatic Diseases|June 1, 1985
Are disease duration and degree of functional impairment determinants of bone loss in rheumatoid arthritis?O S Als, A Gotfredsen, B J Riis, et al.
The Journal of Clinical Endocrinology and Metabolism|April 1, 1990
Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists?B J Riis, C Christiansen, J S Johansen, et al.
Calcified Tissue International|January 1, 1992
Discriminatory ability of bone mass measurements (SPA and DEXA) for fractures in elderly postmenopausal womenK Overgaard, M A Hansen, B J Riis, et al.
Metabolism: Clinical and Experimental|November 1, 1990
Time-dependent variations in bone turnover parameters during 2 months' cyclic treatment with different doses of combined estrogen and progestogen in postmenopausal womenJ S Johansen, S B Jensen, B J Riis, et al.
American Journal of Obstetrics and Gynecology|January 1, 1987
Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal womenJ Jensen, B J Riis, V Strøm, et al.
Human Reproduction (Oxford, England)|September 1, 1992
Serum placental protein 14 (PP14) reflects endometrial status during hormone replacement therapyI Byrjalsen, L Thormann, B Meinecke, et al.
Pageof 13

Showing results (61-70 of 128) with videos related to

Sort By:
Pageof 13
BMC Clinical Pharmacology|September 11, 2008
Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: the effect of water and timing of meal intake on oral delivery of Salmon CalcitoninMorten A Karsdal, Inger Byrjalsen, Bente J Riis, et al.
BMC Clinical Pharmacology|December 6, 2008
Investigation of the diurnal variation in bone resorption for optimal drug delivery and efficacy in osteoporosis with oral calcitoninM A Karsdal, I Byrjalsen, B J Riis, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|February 1, 1991
Potential risk factors for development of postmenopausal osteoporosis--examined over a 12-year periodM A Hansen, K Overgaard, B J Riis, et al.
BMJ (Clinical Research Ed.)|August 19, 1989
Effect of salcatonin given intranasally on early postmenopausal bone lossK Overgaard, B J Riis, C Christiansen, et al.
Annals of the Rheumatic Diseases|June 1, 1985
Are disease duration and degree of functional impairment determinants of bone loss in rheumatoid arthritis?O S Als, A Gotfredsen, B J Riis, et al.
The Journal of Clinical Endocrinology and Metabolism|April 1, 1990
Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists?B J Riis, C Christiansen, J S Johansen, et al.
Calcified Tissue International|January 1, 1992
Discriminatory ability of bone mass measurements (SPA and DEXA) for fractures in elderly postmenopausal womenK Overgaard, M A Hansen, B J Riis, et al.
Metabolism: Clinical and Experimental|November 1, 1990
Time-dependent variations in bone turnover parameters during 2 months' cyclic treatment with different doses of combined estrogen and progestogen in postmenopausal womenJ S Johansen, S B Jensen, B J Riis, et al.
American Journal of Obstetrics and Gynecology|January 1, 1987
Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal womenJ Jensen, B J Riis, V Strøm, et al.
Human Reproduction (Oxford, England)|September 1, 1992
Serum placental protein 14 (PP14) reflects endometrial status during hormone replacement therapyI Byrjalsen, L Thormann, B Meinecke, et al.
Pageof 13